CoChat

84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy

The DOI matches its Crossref record.

Abstract

Data for patients with type 2 diabetes (T2D) on long-acting insulin (LAI) or non-insulin therapy using continuous glucose monitors is limited. This study evaluates change in HbA1c from baseline to 6mo and baseline to 12mo after starting a FreeStyle Libre system for T2D patients on LAI and non-insulin (including GLP-1) therapy. A retrospective, observational analysis was performed by linking data from the LibreView® data management platform, DRG (a commercial medical and pharmacy claims database), and Quest lab HbA1c. Only deidentified data was used for analysis. Index was the first date of data in LibreView (Nov 2017-Sept 2019). Medication and diagnosis were from DRG. HbA1c tests were from Quest. Baseline A1c must be ≥ 6.5% within 6mo prior to index. HbA1c tests closest to +180 days (+150-210) used for 6mo; closest to +360 days (+330-390) used for 12mo. The 6mo T2D cohort (n=774) reduced HbA1c by -0.8%. The 12mo T2D cohort (n=207) reduced HbA1c by -0.6%. The greatest reduction in HbA1c was seen in the T2D non-insulin group at 6mo (-0.9%, n=497) and 12mo (-0.7% n=120). All groups saw clinically significant reduction in HbA1c (Table). Reduction in HbA1c post-FreeStyle Libre use supports the real-world effectiveness of the system in T2D patients using long-acting insulin or non-insulin therapies. Disclosure: E. Miller: None. L. Brandner: Employee; Self; Abbott Laboratories. E. Wright: Advisory Panel; Self; Abbott, Sanofi. Consultant; Self; Abbott, AstraZeneca, Bayer U.S., Boehringer Ingelheim Pharmaceuticals, Inc., MannKind Corporation, Merck & Co., Inc., Voluntis France. Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2337/db20-84-lb

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 23

Metadata

Authors
MILLER, E., BRANDNER, L., & WRIGHT, E.
Affiliations
Bend, OR, Alameda, CA, Charlotte, NC
Venue
Diabetes
Published
2020-06-01
Volume
69
Issue
Supplement_1
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W3035393026
Cited by
23
References
0
Citations by year
2026: 1 · 2025: 5 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 10 · 2020: 2
FWCI
3.03
Type
journal article
Language
en
Open access
closed
Locations
Diabetes (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 2 diabetes, HbA1c reduction, FreeStyle Libre, continuous glucose monitoring, long-acting insulin, non-insulin therapy, GLP-1 receptor agonists, glycemic control, real-world effectiveness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy. https://app.cochat.ai/papers/10.2337/db20-84-lb
The paper
MILLER, E., BRANDNER, L., & WRIGHT, E. (2020). 84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy. Diabetes. https://doi.org/10.2337/db20-84-lb

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.